Xenon Pharmaceuticals (XENE) Fundamental Analysis: Revenue, Earnings & Valuation

5.26 / 10

Netural

Fundamental analysis scores 5.3/10 (neutral). Strengths include PB‑ROE, Revenue‑MV, Cash‑MV and high inventory turnover. Weaknesses lie in Asset‑MV and modest asset efficiency. Gross margin is solid at 100%, but cost of sales and tax ratios limit upside.

Analysis Checks(9/10)

Revenue-MV

Value-0.11

Score2/3

Weight19.97%

1M Return8.45%

Total operating revenue (YoY growth rate %)

Value134.00

Score3/3

Weight3.17%

1M Return1.54%

Inventory turnover ratio

Value103.94

Score3/3

Weight16.27%

1M Return6.74%

Gross profit margin (%)

Value100.00

Score2/3

Weight3.71%

1M Return1.69%

PB-ROE

Value4.35

Score3/3

Weight25.53%

1M Return9.74%

Income tax / Total profit (%)

Value-0.29

Score2/3

Weight2.18%

1M Return1.04%

Fixed assets turnover ratio

Value0.45

Score2/3

Weight-1.08%

1M Return-0.51%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight9.41%

1M Return4.32%

Asset-MV

Value-0.55

Score0/3

Weight6.39%

1M Return2.69%

Cash-MV

Value0.02

Score2/3

Weight14.46%

1M Return5.94%

Is XENE fundamentally strong?

XENE scores 5.26/10 on fundamentals and holds a Fair valuation at present. Backed by its -51.76% ROE, -4612.13% net margin, -15.64 P/E ratio, 9.30 P/B ratio, and -44.85% earnings growth, these metrics solidify its Netural investment rating.